Conference
Nivolumab in squamous cell carcinomas of the head and neck (SCCHN): A real-world outcome study in Ontario, Canada.
Abstract
e18017
Background: The CheckMate-141 trial led to the approval of nivolumab in platinum-resistant metastatic squamous cell carcinomas of the head and neck (SCCHN). We evaluated outcomes of SCCHN patients in Ontario, Canada treated with nivolumab since its funding through the New Drug Funding Program (NDFP) of Cancer Care Ontario (CCO). Methods: Retrospective review using the provincial treatment registry (CCO NDFP) was …
Authors
Zereshkian A; Shafi R; Pond GR; Hotte SJ
Volume
40
Pagination
pp. e18017-e18017
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
June 1, 2022
DOI
10.1200/jco.2022.40.16_suppl.e18017
Conference proceedings
Journal of Clinical Oncology
Issue
16_suppl
ISSN
0732-183X